ClinicalTrials.Veeva

Menu
A

Adams Clinical | Watertown, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3002813
Donanemab
Pimavanserin
BHV-7000
norepinephrine
Rapastinel
BI 1569912
Esketamine
Remternetug
Seltorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 30 total trials

A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (VOYAGE) (Voyage)

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized A...

Enrolling
Generalized Anxiety Disorder
Drug: MM120 (LSD D-Tartrate)
Other: Placebo

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Enrolling
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic A...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is t...

Enrolling
Depressive Disorder, Major
Drug: Placebo matching BI 1569912
Drug: BI 1569912

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did...

Enrolling
Depressive Disorder, Major
Drug: BI 1569912
Drug: Placebo

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

Trial sponsors

Lilly logo
A
Janssen (J&J Innovative Medicine) logo
Acadia Pharmaceuticals logo
Allergan logo
Biohaven logo
Biohaven logo
Boehringer Ingelheim logo
AbbVie logo
Athira Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems